About Zimmer Biomet Holdings, Inc.
https://www.zimmerbiomet.comZimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
CEO
Ivan Tornos
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-03-01 | Forward | 103:100 |
ETFs Holding This Stock
Summary
Showing Top 3 of 707
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
BTIG
Buy
Stifel
Buy
JMP Securities
Market Outperform
RBC Capital
Outperform
Raymond James
Outperform
Morgan Stanley
Equal Weight
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:23.29M
Value:$2.08B
DODGE & COX
Shares:23.22M
Value:$2.07B
BLACKROCK INC.
Shares:16.84M
Value:$1.5B
Summary
Showing Top 3 of 1,381
About Zimmer Biomet Holdings, Inc.
https://www.zimmerbiomet.comZimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2B ▼ | $1.09B ▼ | $230.9M ▲ | 11.54% ▲ | $1.17 ▲ | $638.2M ▲ |
| Q2-2025 | $2.08B ▲ | $1.19B ▲ | $152.8M ▼ | 7.36% ▼ | $0.77 ▼ | $575.7M ▲ |
| Q1-2025 | $1.91B ▼ | $1.07B ▲ | $182M ▼ | 9.53% ▼ | $0.92 ▼ | $549.6M ▼ |
| Q4-2024 | $2.02B ▲ | $1.05B ▲ | $239.5M ▼ | 11.84% ▼ | $1.2 ▼ | $614.5M ▲ |
| Q3-2024 | $1.82B | $1.01B | $249.1M | 13.66% | $1.23 | $535.5M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $1.29B ▲ | $23.49B ▲ | $10.72B ▲ | $12.76B ▲ |
| Q2-2025 | $556.9M ▼ | $22.87B ▲ | $10.33B ▲ | $12.53B ▲ |
| Q1-2025 | $1.38B ▲ | $22.18B ▲ | $9.78B ▲ | $12.4B ▼ |
| Q4-2024 | $525.5M ▼ | $21.37B ▼ | $8.89B ▼ | $12.47B ▲ |
| Q3-2024 | $569M | $21.72B | $9.34B | $12.37B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $231.2M ▲ | $418.7M ▲ | $-163.3M ▲ | $483.8M ▲ | $735.8M ▲ | $545.8M ▲ |
| Q2-2025 | $153.4M ▼ | $378.2M ▼ | $-1.38B ▼ | $163.8M ▼ | $-827.6M ▼ | $298.1M ▼ |
| Q1-2025 | $182.6M ▼ | $382.8M ▼ | $-106M ▲ | $575.4M ▲ | $859M ▲ | $335.8M ▼ |
| Q4-2024 | $240.1M ▼ | $506.3M ▲ | $-291.2M ▼ | $-240.6M ▼ | $-43.5M ▼ | $421.4M ▲ |
| Q3-2024 | $249.2M | $395.7M | $-154.9M | $-101.9M | $148.9M | $368.6M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Hips | $520.00M ▲ | $500.00M ▼ | $540.00M ▲ | $510.00M ▼ |
 Knees | $840.00M ▲ | $790.00M ▼ | $830.00M ▲ | $790.00M ▼ |
 Other Product Category | $170.00M ▲ | $150.00M ▼ | $160.00M ▲ | $0 ▼ |
 S E T | $490.00M ▲ | $470.00M ▼ | $550.00M ▲ | $540.00M ▼ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Americas | $1.27Bn ▲ | $1.20Bn ▼ | $1.27Bn ▲ | $1.25Bn ▼ |
 Asia Pacific | $310.00M ▲ | $260.00M ▼ | $340.00M ▲ | $330.00M ▼ |
 EMEA | $440.00M ▲ | $440.00M ▲ | $470.00M ▲ | $420.00M ▼ |
CEO
Ivan Tornos
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2022-03-01 | Forward | 103:100 |
ETFs Holding This Stock
Summary
Showing Top 3 of 707
Ratings Snapshot
Rating : B+
Most Recent Analyst Grades
BTIG
Buy
Stifel
Buy
JMP Securities
Market Outperform
RBC Capital
Outperform
Raymond James
Outperform
Morgan Stanley
Equal Weight
Grade Summary
Showing Top 6 of 17
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:23.29M
Value:$2.08B
DODGE & COX
Shares:23.22M
Value:$2.07B
BLACKROCK INC.
Shares:16.84M
Value:$1.5B
Summary
Showing Top 3 of 1,381